The Clinical Assessment of Protease-Activated Receptor-2 Expression in Inflammatory Cells from Peripheral Blood and Bronchoalveolar Lavage Fluid in Idiopathic Pulmonary Fibrosis = The Clinical Assessment of Protease-Activated Receptor-2 Expression in Inflammatory Cells from Peripheral Blood and Bronchoalveolar Lavage Fluid in Idiopathic Pulmonary Fibrosis

다국어 초록 (Multilingual Abstract)

Background: Idiopathic pulmonary fibrosis (IPF) is a lethal pulmonary fibrotic disease. In general, the exaggerated activation of the coagulation cascade has been observed during initiation or maintenance of the fibrotic disease. In our recent study, immunohistochemical expression of protease-activated receptor-2 (PAR-2), which plays a key role in coagulation cascade, was observed in surgical specimen of IPF patients, and associated with poor clinical outcome. The aim of this study was to evaluate the overexpression of PAR-2 in inflammatory cells from peripheral blood and bronchoalveolar lavage fluid in IPF patients. Methods: From May 2011 to March 2012, IPF patients and controls were enrolled in Seoul National University Hospital. Peripheral blood and bronchoalveolar lavage fluid were collected for analysis of PAR-2 expression. Flow cytometry and reverse transcription polymerase chain reaction were used for PAR-2 receptor and mRNA assessment. Results: Twelve IPF patients and 14 controls were included in this study. Among them, flow cytometry analysis was conducted from 26 peripheral blood (patient group, 11; control group, 13) and 7 bronchoalveolar lavage fluid (patient group, 5; control group, 2). The expression of PAR-2 receptor was not different between patient and control groups (p=0.074). Among all 24 population, PAR-2 mRNA assessment was performed in 19 persons (patient group, 10; control group, 9). The mRNA expression of PAR-2 was not significant different (p=0.633). Conclusion: In IPF patients, PAR-2 receptor and mRNA expression were not different from control group.

참고문헌 (Reference)

1 Imokawa S, "Tissue factor expression and fibrin deposition in the lungs of patients with idiopathic pulmonary fibrosis and systemic sclerosis" 156 (156): 631-636, 1997

2 Hernandez-Rodriguez NA, "Role of thrombin in pulmonary fibrosis" 346 : 1071-1073, 1995

3 Wygrecka M, "Role of protease- activated receptor-2 in idiopathic pulmonary fibrosis" 183 : 1703-1714, 2011

4 Knight DA, "Protease-activated receptors in human airways: upregulation of PAR-2 in respiratory epithelium from patients with asthma" 108 : 797-803, 2001

5 Peters T, "Protease-activated receptors and prostaglandins in inflammatory lung disease" 158 : 1017-1033, 2009

6 Borensztajn K, "Protease-activated receptor-2 induces myofibroblast differentiation and tissue factor up-regulation during bleomycin-induced lung injury: potential role in pulmonary fibrosis" 177 : 2753-2764, 2010

7 Lewkowich IP, "Protease-activated receptor 2 activation of myeloid dendritic cells regulates allergic airway inflammation" 12 : 122-, 2011

8 Chambers RC, "Procoagulant signalling mechanisms in lung inflammation and fibrosis: novel opportunities for pharmacological intervention" 153 (153): S367-S378, 2008

9 Nystedt S, "Molecular cloning of a potential proteinase activated receptor" 91 : 9208-9212, 1994

10 Nystedt S, "Molecular cloning and functional expression of the gene encoding the human proteinase- activated receptor 2" 232 : 84-89, 1995

11 Harari S, "Idiopathic pulmonary fibrosis" 60 : 421-435, 2005

12 Caminati A, "IPF: new insight in diagnosis and prognosis" 104 (104): S2-S10, 2010

13 Miotto D, "Expression of protease activated receptor-2 (PAR-2) in central airways of smokers and non-smokers" 57 : 146-151, 2002

14 Park YS, "Clinical implication of protease-activated receptor- 2 in idiopathic pulmonary fibrosis" 107 : 256-262, 2013

15 D'Andrea MR, "Characterization of protease- activated receptor-2 immunoreactivity in normal human tissues" 46 : 157-164, 1998

16 Selman M, "American Thoracic Society; European Respiratory Society; American College of Chest Physicians. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy" 134 : 136-151, 2001

17 American Thoracic Society, "American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001" 165 : 277-304, 2002

18 Gunther A, "Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia: comparison with the acute respiratory distress syndrome" 161 (161): 454-462, 2000

19 Noth I, "A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis" 186 : 88-95, 2012